

Article

# Antioxidant and Anti-Aging Phytoconstituents from *Faucaria tuberculosa*: In Vitro and In Silico Studies

Hayam S. Ahmed <sup>1,†</sup>, Hala Abouzeid <sup>2,†</sup>, Mostafa A. Mansour <sup>3</sup> , Asmaa I. Owis <sup>1,4</sup> , Elham Amin <sup>1,5,\*</sup> , Hany W. Darwish <sup>6</sup>, Ashwag S. Alanazi <sup>7</sup> , Ibrahim A. Naguib <sup>8</sup>  and Naglaa Afifi <sup>1,\*</sup>

<sup>1</sup> Department of Pharmacognosy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt; asmaa\_owis@yahoo.com (A.I.O.)

<sup>2</sup> Department of Pharmacognosy, Faculty of Pharmacy, Port Said University, Port Said 42515, Egypt

<sup>3</sup> Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Nahda University, Beni-Suef 62521, Egypt

<sup>4</sup> Department of Pharmacognosy, Faculty of Pharmacy, Heliopolis University for Sustainable Development, Cairo 11785, Egypt

<sup>5</sup> Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia

<sup>6</sup> Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia

<sup>7</sup> Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh 11671, Saudi Arabia

<sup>8</sup> Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia; i.abdelaal@tu.edu.sa

\* Correspondence: EL.saleh@qu.edu.sa (E.A.); naglaa.ahmed@pharm.bsu.edu.eg (N.A.)

† These authors contributed equally to this work.



**Citation:** Ahmed, H.S.; Abouzeid, H.; Mansour, M.A.; Owis, A.I.; Amin, E.; Darwish, H.W.; Alanazi, A.S.; Naguib, I.A.; Afifi, N. Antioxidant and Anti-Aging Phytoconstituents from *Faucaria tuberculosa*: In Vitro and In Silico Studies. *Molecules* **2023**, *28*, 6895. <https://doi.org/10.3390/molecules28196895>

Academic Editor: Alessandra Guerrini

Received: 31 August 2023

Revised: 27 September 2023

Accepted: 29 September 2023

Published: 30 September 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

**Abstract:** Research targeting natural cosmeceuticals is now increasing due to the safety and/or limited side effects of natural products that are highly valued in cosmetology. Within a research program exploring botanical sources for valuable skincare antioxidant components, the current study investigated the phytochemical content and the biological potential of *Faucaria tuberculosa*. Phytochemical investigation of *F. tuberculosa* extract resulted in purification and characterization of six phytoconstituents, including a new one. The structure of the new constituent was elucidated as (-) catechin-(2→1',4→2')-phloroglucinol (**4**). The structural identity of all isolated compounds were confirmed on the basis of extensive physical and spectral (1D, 2D-NMR and HRESIMS) investigations. The ethanolic extract exhibits a rich content of total phenolics (TPC) and total flavonoids (TFC), estimated as  $32 \pm 0.034$  mg GAE/g and  $43 \pm 0.004$  mg RE/g, respectively. In addition, the antioxidant (ABTS and FRAP), antihyaluronidase and antityrosinase activities of all purified phytoconstituents were evaluated. The results noted (-) catechin-(2→1',4→2') phloroglucinol (**4**) and phloroglucinol (**1**) for their remarkable antioxidant activity, while isorhamnetin 3-O-rutinoside (**3**) and 3,5-dihydroxyphenyl β-D-glucopyranoside (**2**) achieved the most potent inhibitory activity against tyrosinase ( $IC_{50}$   $22.09 \pm 0.7$  μM and  $29.96 \pm 0.44$  μM, respectively) and hyaluronidase enzymes ( $IC_{50}$   $49.30 \pm 1.57$  μM and  $62.58 \pm 0.92$ , respectively) that remarkably exceeds the activity of the standard drugs kojic acid ( $IC_{50} = 65.21 \pm 0.47$  μM) and luteolin, ( $IC_{50} = 116.16 \pm 1.69$  μM), respectively. A molecular docking study of the two active compounds (**3** and **2**) highlighted their high potential to bind to the active sites of the two enzymes involved in the study.

**Keywords:** anti-aging; antioxidant; *Faucaria tuberculosa*; hyaluronidase enzyme; tyrosinase enzyme; molecular docking simulation

## 1. Introduction

Aizoaceae is an important plant family predominant mainly in tropical and subtropical areas, and most of its members are ornamental [1]. It includes approximately 135 genera and 2499 species [2]. *Faucaria* is one of these genera, with the subfamily Ruschioideae,

known as Tiger jaws due to its appearance [3]. *Faucaria tuberculosa* (Rolfe) Schwant (Syn, *F. felina* subsp. *tuberculosa* (Rolfe) L.E.Groen, and *Mesembryanthemum tuberosum* (Rolfe)) have special appeal due to the marked tubercles on the upper surface of the leaves making them look like rough stone [4,5]. Reviewing the relevant literature, no research discussing the phytochemical or the biological activity of this species exists, so the current study was undertaken to explore this plant species.

Skin aging is an undesirable multifaceted process causing unwanted signs, e.g., dryness of the skin, wrinkles, hyper-pigmentation, reduced skin elasticity, and skin cancer. Unwanted side effects and allergic reactions, caused by synthetic drugs, have prompted a search for safe, natural anti-aging products. Aging can be classified as intrinsic and extrinsic. Intrinsic aging might be attributable to genetic or hormonal factors while the extrinsic aging may result from exposure to toxins, chemicals, and UV radiation [6–8]. Photo aging is usually accompanied by the formation of reactive oxygen species (ROS). Skin alteration is mediated by many factors including oxidative stress. Accordingly, antioxidants, such as polyphenols, could be an effective treatment that reduces oxidative stress and improves skin condition [9]. The aging process is also associated with increasing enzyme activity as tyrosinase and hyaluronidase [7]. Tyrosinase enzymes regulate the process of melanin synthesis, and melanin accumulation leads to several skin ailments, such as wrinkles, brown spots, age spots, etc. [10]. Hyaluronic acid is a substance produced naturally by the body to preserve moisture content in skin tissues as well as in other organs, and hyaluronidase is the enzyme responsible for hyaluronic acid degradation [11].

In vitro studies assessing the antioxidant and antiaging activity of Aizoaceae extracts were previously reported, in which extracts of *Mesembryanthemum Nodiflorum*, *Mesembryanthemum crystallinum*, *Mesembryanthemum forsskaolii*, *Carpobrotus edulis* and *Mesembryanthemum edule* were reported to possess a concentration-dependent free radical scavenging activity against DPPH and hydrogen peroxide radicals, which was comparable with standard ascorbic acid [12]. Additionally, *Carpobrotus edulis* aqueous leaf extract was reported to increase wound closure, collagen production, and inhibit collagenase and hyaluronidase [13]. In cell culture experiments, CAE increased wound closure and collagen production, which was consistent with its high polyphenol content. Many pure compounds from different chemical classes (e.g., alkaloids, flavonoids, steroids) have been isolated from Aizoaceae plants and were found responsible for their multiple therapeutic activities, such as antioxidant, anti-inflammatory, antihepatotoxic, anticancer, and antimicrobial activities [14]. Since *F. tuberculosa* has not been previously investigated phytochemically and/or biologically, and preliminary studies have shown promising contents of total phenolics and flavonoids, the authors conducted this study with regard to the isolation of secondary metabolites and evaluation of their antioxidant potential, anti-tyrosinase, and anti-hyaluronidase properties. Firstly, an in vitro model was designed to identify the compound(s) with the highest anti-aging activity; secondly, in silico models were applied to the most active anti-aging compound on the two enzymes.

## 2. Results and Discussion


### 2.1. Evaluation of TPC and TFC of Ethanolic Extract

TPC was quantitated using Folin–Ciocalteu reagent, while aluminium chloride was used to determine TFC in *F. tuberculosa* ethanolic extract. The current findings calculate TPC and TFC as  $32 \pm 0.034$  mg GAE/g and  $43 \pm 0.004$  mg RE/g, respectively. These results indicated an appreciable content of phenolics and flavonoids in this species, which may make it promising in terms of biological activities. It worth mentioning that this is the first study investigating the phytoconstituents contents in genus *Faucaria*.

### 2.2. Spectroscopic Data of Isolated Compounds

Chromatographic fractionation of the polar fractions of *F. tuberculosa* afforded five compounds (Figure 1); phloroglucinol (1), 3,5-dihydroxyphenyl  $\beta$ -D-glucopyranoside (Phlorin; 2), isorhamnetin 3-O-rutinoside (3), (-) catechin-(2 $\rightarrow$ 1' $\rightarrow$ 4 $\rightarrow$ 2')-phloroglucinol (4), and isorham-

netin 3-*O*-[ $\alpha$ -rhamnopyranosyl-(1 $\rightarrow$ 4)- $\alpha$ -rhamnopyranosyl-(1 $\rightarrow$ 6)- $\beta$ -glucopyranoside (5).  $\beta$ -sitosterol (6) was purified from the non-polar fraction. Herein, compound 4 is reported as a new natural compound, while other phytoconstituents are isolated for the first time from *F. tuberculosa*.




**Figure 1.** Structures of the phytoconstituents (1–6) from *F. tuberculosa*.

Interestingly, the current study reports the isolation of compound 4 from nature for the first time. The structural elucidation of 4 was performed using physical and spectrophotometric studies. Other known compounds were identified based on their NMR spectral data, and confirmed by comparison with the relevant data reported in the literature [15–20].

Compound 4 was isolated as a pale brown amorphous powder. It becomes an orange colour in response to *p*-anisaldehyde-sulphuric acid spray reagent, a colour characteristic of proanthocyanidin compounds [21]. It displays peaks at 224 and 278 nm in the UV spectrum,  $[\alpha]_D^{25} = -9$  (MeOH), and a molecular ion peak,  $[M-H]^-$ , with  $m/z$  573.1323 recorded in the HRMS spectrum (Figure S7).

$^1\text{H-NMR}$  (Table 1, Figure S8) displayed signals at  $\delta_{\text{H}}$  4.06 (d,  $J = 3.6$  Hz; H-3), 4.65 (d,  $J = 4$  Hz; H-4), representing an AB system, in addition to an AMX coupling system:

$\delta_{\text{H}}$  7.13 (d,  $J = 2.4$ , H-10), 6.83 (d,  $J = 2.4$ , H-13), 7.01 (dd,  $J = 2, 8.2$ , H-14). In the  $^{13}\text{C}$  NMR and HSQC spectra (Figures S9 and S10), the presence of signals at  $\delta_{\text{C}}$  100.3, 68.08 and 29.5 is attributed to the heterocyclic C-2, C-3, and C-4 of ring C. The aromatic A-, B- and D-ring carbons were observed downfield at  $\delta_{\text{C}}$  104.5 (4a), 155.5(5), 98.6(6), 156.2(7), 96.9(8), 158.6(8a), 132.1(9), 115.65(10), 146.7(11), 145.7(12), 115.67(13) and 119.8(14). These spectral data were similar to data for the upper flavanol moiety of the previously reported proanthocyanidin A-2; epicatechin-(2 $\beta$ →7,4 $\beta$ →8)-epicatechin [21]; however, NOE data were recorded to confirm cis or trans configuration of H-3, H-4 and H-14, as indicated below. Proanthocyanidins are oligomers or polymers composed of flavanol units. They are classified into subclasses; among them, the A-type is a subclass characterized by a double linkage between two consecutive flavanol moieties. One of them is a single 4C-8D or 4C-6D bond, while the other is ether-type bond between 2C-O-7D or 2C-O-5D [22,23]. NMR spectral data for compound 4 differ from proanthocyanidin A-2 in the absence of signals of a lower flavanol moiety. As indicated in Table 1, both  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR data showed characteristic resonances for a 1, 2 disubstituted phloroglucinol moiety ( $\delta_{\text{C}}$  108.2, 154.4, 98.1, 154.9, 96.8, 158) and a  $\beta$ -glucopyranoside moiety ( $\delta_{\text{C}}$  101.9, 74.6, 77.3, 71.2, 78.2, 62.3). HMBC (Table 1, Figure S11) showed  $^2J_{\text{C-H}}$  correlation between H-4 and C-4a and  $^3J_{\text{C-H}}$  correlation between H-4 and, C-2, C-2', C-3' confirming the linkage between the flavanol and phloroglucinol moieties. This double-linked skeleton was confirmed by presence of one acetal carbon at  $\delta_{\text{C}}$  100.3 (C-2) and one quaternary carbon at  $\delta_{\text{C}}$  108.2 (C-2') in its  $^{13}\text{C}$  NMR spectrum. The identities of the sugar units were elucidated via comparison of their  $^{13}\text{C}$  NMR resonances with the literature [17,24]. The anomeric proton exhibited a  $J$  value of 7.6 Hz, thus confirming  $\beta$ -type glycosidic linkage [17,24]. The position of the glucopyranoside moiety was elucidated in the HMBC spectrum, as it displayed a  $^3J_{\text{C-H}}$  correlation between the anomeric proton of the glucose moiety at  $\delta_{\text{H}}$  4.97(d, 7.6, H-1'') to 5' at  $\delta_{\text{C}}$  154.9 ppm. Based on their similarity with A-type proanthocyanidins, H-3 and H-4 cis or trans orientation cannot be distinguished based on coupling constants that record very similar values. However, they can be determined via NOE correlation (Figures S12 and S13). H-3 showed a NOE interaction with H-14; a NOE interaction, characteristic of a 3, 4-trans orientation, was not detected between H-3C with H-6D. Accordingly, the interaction between H-3C and H-4C is cis, and independently of the rigid ring conformation, the flavanol moiety will be catechin [23,25]. Accordingly, compound 4 was concluded as (-) catechin-(2→1',4→2')-phloroglucinol (Figures 1 and 2), which was isolated as a natural product herein for the first time.



**Figure 2.** Key HMBC (blue colour) and NOESY (red colour) correlations.



**Table 1.** NMR spectroscopic data of compound 4.

Position	$\delta_{\text{H}}$ (mult, J)	$\delta_{\text{C}}$	HMBC (H→C)
Flavanol moiety			
2	----	100.3	----
3	4.05 (d, 3.6)	68.08	C-4a
4	4.64 (d, 4)	29.5	C-4a, C-2, C-2', C-3'
4a	----	104.5	----
5	----	155.5	----
6	6.03(d, 2.4)	98.6	C-4a
7	----	156.2	----
8	6.10 (d, 2.4)	96.9	----
8a	----	158.6	----
9	----	132.1	----
10	7.13 (d, 2.4)	115.65	C-2, C-9, C-11, C-12, C-14
11	----	146.7	----
12	----	145.7	----
13	6.81 (d, 8.4)	115.67	C-2, C-11, C-12, C-14
14	7.01 (dd, 2, 8.4)	119.8	C-2, C-9, C-10, C-12, C-13
Phloroglucinol moiety			
2'	----	108.1	
3'	----	154.5	
4'	6.08 (d, 2)	98.1	C-2', C-5'
5'	----	154.9	
6'	6.23 (d, 2.4)	96.8	C-1', C-2'
1'	----	158.1	----
$\beta$ -glucopyranoside moiety			
1''	4.95 (d, 7.6)	101.9	C-5'
2''	3.604 (dd, 1.6, 7.2)	74.6	
3''	3.53 (m)	77.3	
4''	3.46 (d, 4.8)	71.2	
5''	3.46 (d, 4.8)	78.2	
6''	3.73 (m, H-6' a)		
	3.92 (m, H-6' b)	62.3	

### 2.3. Antioxidant Activities of Isolated Compounds

ROS are regularly generated in most living tissues. They can damage DNA, proteins and lipids at high concentrations. Several studies have reported that ROS plays a key role in the mechanism of aging [26–28]. To evaluate the antioxidant activity of the isolated compounds (1–6), we examined their ABTS<sup>+</sup> radical scavenging capacity, as well as the total reducing power (FRAP). The antioxidant activity of phenolics is affected by their chemical structures; OH groups represent a key factor regulating the ability of these compounds to scavenge the free radicals hydroxyl [29,30]. As indicated in Table 2, the two compounds catechin-(2→1',4→2')-phloroglucinol (4) and phloroglucinol (1) exhibited strong ABTS radical scavenging activity with IC<sub>50</sub> values of 4.11 ± 0.32 and 6.44 ± 0.47 µg/mL, respectively, which seems better than the standard used (ascorbic acid). Additionally, compounds 3, 5 and 2 showed good antioxidant, while 6 was the least active among the tested compounds. Interestingly, the results of the ferric reducing antioxidant power (FRAP) assay were in great accordance with the ABTS radical scavenging assay results, wherein catechin-(2→1',4→2')-phloroglucinol and phloroglucinol showed the strongest reducing power, with IC<sub>50</sub> values better than ascorbic acid (Table 2). The strong antioxidant activity of catechin-(2→1',4→2')-phloroglucinol may be returned to the linkage between the flavan and phloroglucinol moieties, as well as the hydroxyl groups after the pattern of A-type proanthocyanidin [30]. The strong ABTS radical scavenging activity of phloroglucinol was consistent with the previously reported data [31]. This remarkable antioxidant activity was attributed to the presence of acidic hydrogen [32]. Compound 5 exhibited antioxidant and reducing powers, with an IC<sub>50</sub> lower than compound 3. The decrease in the activity of both flavonoids may be related to their glycosylation at C-3 [33].

**Table 2.** Antioxidant activities of the isolated compounds (1–6) from *F. tuberculosis*.

Compound No.	Compound Name	IC <sub>50</sub> Value (μg/mL)	
		ABTS Assay	FRAP Assay
1	Phloroglucinol	6.44 ± 0.47	12.89 ± 0.93
2	Phlorin	43.40 ± 3.18	64.52 ± 4.15
3	Isorhamnetin 3- <i>O</i> -rutinoside	12.24 ± 0.61	25.24 ± 2.03
4	(-) Catechin-(2→1',4→2')-phloroglucinol	4.11 ± 0.32	7.36 ± 0.57
5	Isorhamnetin 3- <i>O</i> -[α-rhamnopyranosyl-(1→4)-α-rhamnopyranosyl-(1→6)-β-glucopyranoside]	18.19 ± 2.94	35.04 ± 2.89
6	β-sitosterol	557.46 ± 19.76	ND
	Positive standard (Ascorbic acid)	10.67 ± 0.85	20.86 ± 1.28


All values are expressed as mean ± SD ( $n = 3$ ).

The moderate activity of phlorin (2) (when compared with phloroglucinol) also matched the reported DPPH radical scavenging activity of its butanoyl derivative [34]. Hence, presence of more sugar moieties in phlorin (2) and isorhamnetin glycoside (5) causes a reduction in their antioxidant activity. β-sitosterol showed weak ABTS activity and no reducing antioxidant power (FRAP). These results matched those in previous reports of this compound [35].

#### 2.4. Anti-Aging Activities of Isolated Compounds

##### 2.4.1. Tyrosinase Inhibitory Assay


Tyrosinase played an important role in melanin biosynthesis, which in turn leads to age spots [36]. In our study, all the isolated compounds were investigated in vitro for the inhibitory activities of tyrosinase enzymes, using kojic acid (IC<sub>50</sub> = 65.21 ± 0.47 μM) standard. As demonstrated in Figure 3, isorhamnetin 3-*O*-rutinoside (3) and phlorin (2) exhibited an extremely potent tyrosinase inhibition, with IC<sub>50</sub> values of 22.09 ± 0.7 μM and 29.96 ± 0.44 μM, respectively, followed by compounds 4, 5 and 6, which also showed strong activity with IC<sub>50</sub> values of 54.47 ± 1.59 μM, 34.61 ± 1.36 μM and 36.99 ± 0.78 μM, respectively. On the other hand, compound 1 showed very weak activity, with an IC<sub>50</sub> of 722.940 ± 4.64 μM. Remarkably, the current study is the first study that investigates the anti-tyrosinase activity of compounds 1–5. Compound 6 was previously noted for its significant binding affinity with tyrosinase enzymes [36].



**Figure 3.** Anti-tyrosinase activity of the phytoconstituents from *F. tuberculosis*: (C1) phloroglucinol, (C2) phlorin, (C3) isorhamnetin 3-*O*-rutinoside, (C4) (-) catechin-(2→1',4→2')-phloroglucinol, (C5) isorhamnetin 3-*O*-[α-rhamnopyranosyl-(1→4)-α-rhamnopyranosyl-(1→6)-β-glucopyranoside], (C6) β-sitosterol.

## 2.4.2. Hyaluronidase Inhibitory Assay

In vitro investigation of the hyaluronidase inhibitory potential of the isolated compounds, using luteolin ( $IC_{50} = 116.16 \pm 1.69 \mu M$ ) as a standard, indicated similar results to those of the anti-tyrosinase activity testing (Figure 4). Isorhamnetin 3-*O*-rutinoside (3) showed the most potent activity, followed by phlorin (2), with  $IC_{50}$  values of  $49.3 \pm 1.57 \mu M$  and  $62.58 \pm 0.92 \mu M$ , respectively. Additionally, compounds 5 and 6 showed good activity, with  $IC_{50}$  values of  $63.31 \pm 2.84 \mu M$  and  $65.45 \pm 1.38 \mu M$ . Notably, all the four compounds displayed better activity than the standard used. Additionally, (-) catechin-(2→1',4→2')-phloroglucinol (4) displayed medium inhibitory activity ( $IC_{50} 287.39 \pm 8.4 \mu M$ ), while phloroglucinol (1) showed very weak activity, with  $IC_{50}$  values of  $1108.56 \pm 7.11 \mu M$ .




**Figure 4.** Anti-hyaluronidase activity of the phytoconstituents from *F. tuberculosa*: (C1) phloroglucinol, (C2) phlorin, (C3) isorhamnetin 3-*O*-rutinoside, (C4) (-) catechin-(2→1',4→2')-phloroglucinol, (C5) isorhamnetin 3-*O*-[ $\alpha$ -rhamnopyranosyl-(1→4)- $\alpha$ -rhamnopyranosyl-(1→6)- $\beta$ -glucopyranoside], (C6)  $\beta$ -sitosterol.


## 2.5. In Silico Molecular Docking

### 2.5.1. Anti-Tyrosinase Activity


The docking study involved simulation of the most active compounds, isorhamnetin 3-*O*-rutinoside (3) and phlorin (2), compared to the current inhibitor (kojic acid), in the tyrosinase cleavage site (PDB ID: 2Y9X). Figure 5 shows the binding site of the three compounds in the binuclear copper-containing domain. We compared the optimal binding poses of phlorin (2) and isorhamnetin 3-*O*-rutinoside (3) with that of the well-known tyrosinase inhibitor kojic acid. Figures 6–8, respectively, depict the most stable binding poses based on the MOE 2022.01 scoring (described in Table 3) within the catalytic domain of tyrosinase (2D and 3D interaction captions).




**Figure 5.** Phlorin, isorhamnetin 3-*O*-rutinoside and kojic acid bound to the active domain of tyrosinase enzyme (PDB: 2Y9X): (A) 3D binding presentation of tyrosinase enzyme; (B) magnified 3D binding mode showing the active site of a tyrosinase enzyme containing two copper ions and the three docked ligands (phlorin in red, isorhamnetin 3-*O*-rutinoside in blue, and kojic acid in yellow). The figure was generated using BIOVIA Discovery Studio 2021.



**Figure 6.** (A) 2D interaction diagram of the top docking pose of phlorin into the active site of the tyrosinase enzyme; (B) 3D interaction diagram of the top docking pose of phlorin into the active site of the tyrosinase enzyme.



**Figure 7.** (A) Two-dimensional interaction diagram of the top docking pose of isorhamnetin 3-O-rutinoside into the active site of the tyrosinase enzyme; (B) Three-dimensional interaction diagram of the top docking pose of isorhamnetin 3-O-rutinoside into the active site of the tyrosinase enzyme.



**Figure 8.** (A) Two-dimensional interaction diagram of the top docking pose of kojic acid into the active site of the tyrosinase enzyme; (B) Three-dimensional interaction diagram of the top docking pose of kojic acid into the active site of the tyrosinase enzyme.

The demonstrated molecular docking results nicely matched with the *in vitro* testing results, wherein isorhamnetin 3-O-rutinoside (**3**) showed the highest binding score (with a  $-12.154$  kcal/mol binding energy) to the binuclear copper ions of the catalytic domain, with strong metal acceptor bonds to the copper ions. Moreover, it showed strong H-bond acceptance to Met 280 amino acid; also, it formed stable H-bond acceptor bonds with His 85, Val 283, and Asn 81 residues, in addition to many hydrophobic interactions within the binding site of the tyrosinase enzyme. These strong interactions as well as the bulkiness of isorhamnetin 3-O-rutinoside could provide an acceptable explanation of the strong enzyme assay results of this compound against the tyrosinase enzyme. Similarly, phlorin (**2**) showed a strong binding interaction, with a binding affinity of  $-10.953$  kcal/mol, and served as strong metal acceptor of the binuclear copper ions of the catalytic domain. Additionally, it demonstrated an H-bond acceptor interaction with His 85 amino acid, which seems an essential binding residue for this activity. Moreover, it interacted via H-bond donor bonds with Asn 260 and Met 280. In addition, it exhibited hydrophobic interactions with His 244 residue. These strong interactions may explain and match with the enzyme assay results of this compound against tyrosinase enzyme.

**Table 3.** Molecular docking results for compounds phlorin (2) and isorhamnetin 3-*O*-rutinoside (3) during docking in the tyrosinase (PDB ID: 2Y9X) active domain (using kojic acid as reference drug) and the hyaluronidase (PDB ID: 1FCV) active site (using luteolin as reference drug), including binding affinities (kcal/mol), distance (Å) from main residue/metal contact, and the type of the interaction.

Tyrosinase (PDB ID: 2Y9X)				
Compound	Affinity (kcal/mol)	Distance (in Å) from Main Residue		Type of Interaction
Phlorin	−10.935	2.61	Cu400	Metal acceptor
		2.55	Cu401	Metal acceptor
		2.50	His85	H-bond acceptor
		2.82	Asn260	H-bond donor
		2.74	Met280	H-bond donor
		4.93	His244	Hydrophobic
Isorhamnetin 3- <i>O</i> -rutinoside	−12.154	2.12	Cu400	Metal acceptor
		2.26	Cu401	Metal acceptor
		2.36	His85	H-bond acceptor
		2.97	Met280	H-bond donor
		2.27	Val283	H-bond acceptor
		2.53	Asn81	H-bond acceptor
		3.14	His263	Hydrophobic
3.45	Gly281	Hydrophobic		
kojic acid	−9.385	2.96	Cu400	Metal acceptor
		2.63	Cu401	Metal acceptor
		2.34	His85	H-bond acceptor
		2.90	Asn260	H-bond acceptor
		2.78	Met280	H-bond donor
		3.89	His263	Hydrophobic
3.39	Val283	H-bond acceptor		
Hyaluronidase (PDB ID: 1FCV)				
Compound	Affinity (kcal/mol)	Distance (in Å) from Main Residue		Type of Interaction
Phlorin	−14.979	1.91	Asp111	H-bond donor
		2.34	Ser304	H-bond acceptor
		1.93	Glu113	H-bond donor
		2.98	Glu113	H-bond donor
		4.11	Trp301	Hydrophobic
		2.51	Tyr184	H-bond acceptor
Isorhamnetin 3- <i>O</i> -rutinoside	−16.578	2.15	Asp111	H-bond donor
		2.89	Ser304	H-bond acceptor
		2.36	Ser303	H-bond acceptor
		2.41	Ser303	H-bond acceptor
		1.99	Glu113	Electrostatic
		3.14	Trp301	Hydrophobic
		3.54	Tyr55	Hydrophobic
3.22	Asp305	Hydrophobic		
Luteolin	−12.404	2.66	Asp111	H-bond donor
		2.00	Ser304	H-bond acceptor
		3.57	Glu113	Hydrophobic
		4.74	Trp301	Hydrophobic
		4.77	Tyr55	Hydrophobic
		2.45	Asp56	H-bond acceptor
1.95	Asp305	H-bond donor		


On the other hand, the positive control and the reference drug kojic acid showed a strong binding interaction with the active domain of the tyrosinase enzyme, with a binding affinity of −9.385 kcal/mol. It served as strong metal acceptor, and formed




strong bonds to copper ions incorporated at the active site. Kojic acid also showed an H-bond acceptor interaction with His 85 residues, which validates the importance of these amino acids as inhibitors of the tyrosinase enzyme. Kojic acid also bound to Asn 260 and Met 280 residues with H-bond acceptor and H-bond donor interactions, respectively, and showed a hydrophobic interaction with His 263 amino acid and served as an H-bond acceptor for Val 283 residues.

### 2.5.2. Anti-Hyaluronidase Activity


The docking investigation involved simulation of the most potent compounds isorhamnetin 3-*O*-rutinoside (3) and phlorin (2), compared to the current inhibitor luteolin, into the active site of hyaluronidase (PDB ID: 1FCV). Figure 9 shows the binding site of both compounds within the catalytic domain of the hyaluronidase enzyme. Comparing the optimal binding poses of isorhamnetin 3-*O*-rutinoside and phlorin with those of the positive control, luteolin, Figures 10–12 depict the most stable binding poses based on the scoring method of the docking machine (described in Table 3) within the catalytic domain of hyaluronidase (2D and 3D interaction captions).




**Figure 9.** Phlorin, isorhamnetin 3-*O*-rutinoside and luteolin bound to the active domain of the hyaluronidase enzyme (PDB: 1FCV): (A) 3D binding presentation of the hyaluronidase enzyme; (B) magnified 3D binding mode showing active site of the hyaluronidase enzyme containing the three docked ligands (phlorin in red, isorhamnetin 3-*O*-rutinoside in blue, and luteolin in yellow). The figure was generated using BIOVIA Discovery Studio 2021.



**Figure 10.** (A) Two-dimensional interaction diagram of the top docking pose of phlorin into the active site of the hyaluronidase enzyme; (B) Three-dimensional interaction diagram of the top docking pose of phlorin into the active site of the hyaluronidase enzyme.



**Figure 11.** (A) Two-dimensional interaction diagram of the top docking pose of isorhamnetin 3-*O*-rutinoside into the active site of the hyaluronidase enzyme; (B) Three-dimensional interaction diagram of the top docking pose of F3 into the active site of the hyaluronidase enzyme.



**Figure 12.** (A) Two-dimensional interaction diagram of the top docking pose of luteolin into the active site of the hyaluronidase enzyme; (B) Three-dimensional interaction diagram of the top docking pose of luteolin into the active site of the hyaluronidase enzyme.

Isorhamnetin 3-*O*-rutinoside (**3**) showed a very strong interaction with the binding site of the hyaluronidase enzyme, with a  $-16.578$  kcal/mol binding affinity. It exhibited a strong H-bond donor interaction with Asp 111 amino acid, H-bond acceptor interactions with Ser 304 amino acid, and two significant interactions with Ser 303 amino acid, as well as a unique electrostatic interaction with the amino acid Glu 113. Furthermore, a lot of hydrophobic interactions with the catalytic domain of the hyaluronidase enzyme were also displayed.

Phlorin (**2**), the second most active constituent, showed a strong binding interaction with the active domain of the hyaluronidase enzyme, with a binding affinity of  $-14.979$  kcal/mol. It showed excellent H-bond donor interaction, with an Å bond distance of 1.91, with the Asp 111 residue. It exhibited a bidentate H-bond donor interaction with Glu 113 amino acid. Additionally, it formed H-bond acceptor interactions with Ser 304 and Tyr 184 amino acids, and a hydrophobic interaction between the phenyl ring and Trp 301 residue.

These strong interactions notably account for the recorded in vitro anti-enzyme activity of isorhamnetin 3-*O*-rutinoside (**3**) and phlorin (**2**) against the hyaluronidase enzyme.

The reference drug, luteolin, showed a relatively weaker interaction to the active domain of the enzyme, with a binding affinity of  $-12.404$  kcal/mol, if compared to the binding affinities of isorhamnetin 3-*O*-rutinoside (**3**) and phlorin (**2**), which may explain the superior activity of these compounds compared with the positive control luteolin. The binding interactions of luteolin were involved in two H-bond donor interactions with Asp 111 and Asp 305 residues. In addition, it formed three hydrophobic interactions with Glu 113, Trp 301, and Tyr 55 amino acids; it served as an H-bond acceptor for Ser 304 at the edge of the hyaluronidase active domain, and also for Asp 56 residue with the *m*-OH of the phenyl ring.

### 3. Materials and Methods

#### 3.1. Plant Material and Extraction

*F. tuberculosis* (aerial parts) were collected in September 2020 from El-Hosary public garden in 6th October City, Egypt. The plant's identity was taxonomically confirmed by Ms. Trease Labib, El-Orman Botanical Garden, Giza, Egypt. A plant sample (with voucher number BUPD-118) was preserved at the College of Pharmacy, BSU, Egypt. *F. tuberculosis* (750 g, fresh aerial parts) was steeped in ethanol at RT and filtered, and the filtrate was dried under a vacuum to yield a 150 g residue, which was used for evaluation of the total antioxidant activity, TPC, TFC, and chromatographic isolation. For chromatographic isolation, the residue was partitioned using different solvents with sequential polarities; the obtained fractions were then dried under a vacuum.

#### 3.2. General Experimental Materials and Procedures

Silica gel 60 (particle size 0.063–0.2 mm, 70–230 mesh) (Fluka, St. Louis, MO, USA), Polyamide-6 and Sephadex LH-20 (Sigma-Aldrich, Taufkirchen, Germany) were utilized for column chromatography. TLC plates (Si 60 F<sub>254</sub>, Merck, Darmstadt, Germany) and analytical-grade solvents were used in the study. Visualization of the spots was carried out using *p*-anisaldehyde spray reagent [37].

The UV investigation was carried out in methanol utilizing a Shimadzu UV1, 601PC UV–visible scanning spectrophotometer (Shimadzu Corp., Tokyo, Japan). Optical rotation was measured using a 341 Perkin Elmer polarimeter (Darmstadt, Germany). HRESIMS was executed on Agilent LC/Q-TOF, 6530 (Santa Clara, CA, USA). All 1D and 2D NMR spectra were recorded on a Bruker Avance III 400 MHz (Bruker AG, Fällanden, Switzerland) and analysed using Topspin 3.1 software (Bruker AG, Fällanden, Switzerland). Deuterated methanol and chloroform (Cambridge Isotopes, Andover, MA, USA) were used.

Aluminium trichloride ( $\text{AlCl}_3 \cdot 6\text{H}_2\text{O}$ ), anhydrous sodium carbonate ( $\text{Na}_2\text{CO}_3$ ), ascorbic acid, DPPH, ABTS (Sigma, PN: A3219, St. Louis, MO, USA), Folin–Ciocalteu, gallic acid, rutin, sodium hydroxide (NaOH), and sodium nitrite ( $\text{NaNO}_2$ ) were purchased from Merck (Rahway, NJ, USA) and Sigma-Aldrich (St. Louis, MO, USA).

### 3.3. Evaluation of the Total Phenolic Content (TPC) of Ethanolic Extract

The total phenolics in the crude extract was assessed using Folin–Ciocalteu’s reagent according to Jimoh et al., with slight modifications [38]. Ethanol extract (0.5 mL) and 2.25 mL of Folin–Ciocalteu reagent (10% aqueous solution) were mixed, and 5 min later, 2.25 mL of  $\text{Na}_2\text{CO}_3$  (7.5%, *w/v*) was added; the solution was kept for 30 min, and absorbance was then measured at 725 nm using a spectrophotometer. The results were calculated as mg gallic acid equivalents per 1 g of dried extract (mg GAE/g).

### 3.4. Evaluation of the Total Flavonoid Content (TFC) of Ethanolic Extract

Flavonoids contents were measured using the modified colorimetric method. [39] In a test tube, diluted extract (0.5 mL extract + 2.25 mL distilled water) was mixed with 0.15 mL of 5%  $\text{NaNO}_2$  solution, and 6 min later,  $\text{AlCl}_3 \cdot 6\text{H}_2\text{O}$  solution (10%, 0.3 mL) was added; the solution was kept for 5 min, and then 1.0 mL of 1 M NaOH was added. The absorbance was then measured at 510 nm using a spectrophotometer. TFC was estimated as mg rutin equivalents per 1 g of dried extract (mg RE/g).

### 3.5. Chromatographic Isolation of Phytoconstituents

TLC screening of the different fractions revealed similar spots in both ethyl acetate (EtOAc) and butanol (*n*-BuOH) fractions; accordingly, both fractions were combined. The pooled fraction (2.2 g) was fractionated on a polyamide-6 column (80 × 2.8 cm, i.d) with an aqueous methanol gradient to obtain F-I, F-II, and F-III. Fraction F-I (700 mg, eluted with 5% aq. MeOH) was applied on an Si column, using elution with  $\text{CH}_2\text{Cl}_2$  containing increasing proportions of MeOH to attain the sub fractions F-Ia (30 mg) and F-Ib (40 mg). Both fractions were re-chromatographed using Sephadex LH-20 c.c. and eluted with MeOH to isolate compounds **1** (10 mg) and **2** (12 mg). F-II (50 mg, 70% aq. MeOH) was similarly treated to isolate compound **3** (8 mg). Additionally, F-III (50 mg, 90% aq. MeOH) was subjected to the same procedure to obtain compounds **4** (8 mg) and **5** (10 mg).

*n*-hexane extract was subjected to gradient chromatography on a Si gel column, using *n*-hexane-EtOAc mixtures as the mobile phase, to obtain compound **6** (5 mg).

The NMR data for compounds **1**, **2**, **3**, **5** and **6** are included in the supplementary data.

### 3.6. Antioxidant Activities of the Isolated Compounds

The antioxidant activity of the isolated compounds was determined using ABTS and FRAP assays in triplicate, and the average values were considered.

#### 3.6.1. ABTS Radical Scavenging

This is a decolorization assay method in which the antioxidant capacity of the isolated compounds is measured via a reaction with an ABTS cation radical; we adopted the method described by others [40–42]. To produce the ABTS radical, the stock solution of ABTS (1.8 mM) was reacted with potassium persulfate (0.63 mM), and the mixture was kept in the dark, at RT, for 12–16 h. The reaction mixture was then adjusted to obtain 0.700 ( $\pm 0.030$ ) absorbance at 734 nm via dilution with ethyl alcohol. Afterwards, the

radical solution (190  $\mu\text{L}$ ) and sample solution (10  $\mu\text{L}$ ) were mixed, and the absorbance was recorded regularly, at 734 nm, every minute up to a time period of 13 min from initial mixing. Ascorbic acid (standard drug) and 80% methanol (negative control) were similarly treated as the sample solution.

### 3.6.2. Ferric Reducing/Antioxidant Power (FRAP)

Herein, antioxidant potential was measured based on the samples' ability to reduce ferric to ferrous ion [43]. This method relies on the reduction of ferricyanide relative to the sample. Samples (1 mL) were mixed with 2.5 mL of each of sodium phosphate buffer and  $\text{K}_3\text{Fe}(\text{CN})_6$ , and then the reaction mixture was incubated (50  $^\circ\text{C}$ , 20 min). Afterward, 2.5 mL of trichloroacetic acid was added, and centrifugation (1000 $\times g$ , 10 min) was carried out. Some 2.5 mL of the supernatant solution and an equal amount of deionized  $\text{H}_2\text{O}$  and 0.5 mL of ferric chloride were then mixed, and the absorbance was recorded at 700 nm.

## 3.7. Anti-Aging Activities of the Isolated Compounds

The anti-aging potential of the *F. tuberculosis* phytoconstituents was assessed via evaluation of their anti-tyrosinase and anti-hyaluronidase activities. Both assays were carried out in triplicate, and average values were considered.

### 3.7.1. Tyrosinase Inhibitory Assay

To measure tyrosinase activity, a colorimetric assay was performed by using Tyrosinase Inhibitor Screening Kit (# K575-100, BioVision<sup>®</sup> Inc., Milpitas, CA, USA), adopting instructions provided by the manufacturer. Firstly, we added 20  $\mu\text{L}$  of the test inhibitors in serial dilutions (Sample, S), an inhibitor control (IC), and tyrosinase assay buffer into wells (enzyme control, EC). Tyrosinase enzyme solution (50  $\mu\text{L}$ ) was added to each well, and incubated at 25  $^\circ\text{C}$  for 10 min. Then, the tyrosinase substrate solution (30  $\mu\text{L}$ ) was added, and the absorbance was recorded at 510 nm for 30–60 min [44]. The % relative inhibition was calculated as follows:

$$\% \text{ Relative inhibition} = [(\text{Slope of EC} - \text{Slope of S}) / \text{Slope of EC}] \times 100 \quad (1)$$

### 3.7.2. Hyaluronidase Inhibitory Assay

This assay was performed by adopting a turbidimetric assay using a QuantiChrom<sup>™</sup> Hyaluronidase Inhibitor Screening Assay Kit. Bovine hyaluronidase (Calzyme Cat # 091A0300) was mixed with the enzyme buffer until a concentration of 10 U/mL was reached. Then, 40  $\mu\text{L}$  of enzyme solution (sample well), enzyme buffer (NEC), and hyaluronidase (used for NIC) were transferred to a 96-well plate. DMSO (20  $\mu\text{L}$ ) was added to the NIC and NEC wells, while 20  $\mu\text{L}$  samples were added to the sample wells. The plate was then incubated (15 min, RT). Afterwards, 40  $\mu\text{L}$  of the substrate was added, followed by 20 min incubation. Finally, 160  $\mu\text{L}$  of the stop reagent was added, and a further 10 min of incubation was performed; the optical density was then measured at 600 nm [45].

$$\% \text{ Inhibition} = [1 - (\text{OD}_{\text{NEC}} - \text{OD}_{\text{Test Cpd}}) / (\text{OD}_{\text{No Enzyme}} - \text{OD}_{\text{NIC}})] \times 100 \quad (2)$$


where OD is the optical density value, NEC refers to no enzyme control, and NIC refers to no inhibitor control.

## 3.8. In Silico Molecular Docking Studies

### 3.8.1. Anti-Tyrosinase Activity

For the docking study, the crystal structure of *Agaricus bisporus* tyrosinase (PDB code: 2Y9X) [46,47] was downloaded from the protein databank (PDB). Then, the structures of the most active compounds isorhamnetin 3-O-rutinoside and phlorin versus the positive control, kojic acid, were drawn with Marvin Sketch (Chem Axon, Boston, MA, USA) [48] and minimized with the MOE 2022.01 (Chemical Computing Group, Montreal, QC, Canada) Amber10:EHT force field general energy minimizing tool (Gradient RMS < 0.1 kcal/mol/ $\text{\AA}^2$ ) [49].

The docking methods and parameters were validated by redocking the native ligand into its active site to ensure that the ligand orientations and positions derived from docking studies were likely to represent valid and reasonable potential binding modes of the inhibitors. The root mean square deviation (rmsd) between the re-docked native ligand and the co-crystallized ligand was 0.5478, as shown in Figure 13.



**Figure 13.** Tyrosinase enzyme: co-crystallized (light green) and re-docked (yellow) ligands' superimposition.

The most active compounds (3) and (2) and kojic acid were docked into the active domain of tyrosinase. Fifty poses of each compound were scored using the initial rescoring methodology (London dG) and the final rescoring methodology (London dG) after placement using Triangle Matcher. The post-placement refinement was performed using Force Field [50]. The 2D diagrams of the interactions between ligands and amino acid residues were generated using the free BIOVIA Discovery Studio Visualizer 2021 [51], while the 3D captions were generated using the PyMOL (v0.99) program [52].

### 3.8.2. Anti-Hyaluronidase Activity

Anti-hyaluronidase docking experiments were carried out using the crystal structure of bee venom hyaluronidase in complex with a hyaluronic acid tetramer (PDB code: 1FCV) [45,53]. The chemical structures of the most active compounds, isorhamnetin 3-O-rutinoside and phlorin, and the reference drug, luteolin, as a well-known flavone [54,55], were drawn and minimized, as in a previous study [48,49]. In the active domain of hyaluronidase, the most active compounds (3), (2), and luteolin were docked. Fifty poses of each compound were scored using the initial rescoring method (London dG), the final rescoring method (GVBI/WSA dG) after placement using Triangle Matcher; the post-placement refinement was carried out using Force Field [56]. Additionally, the free program BIOVIA Discovery Studio Visualizer 2021 was used to generate the 2D diagrams illustrating the interaction between ligands and amino acid residues [51], while PyMOL (v0.99) was employed in the generation of the 3D captions [52].

## 4. Conclusions

The phytochemical study of *F. tuberculosa* resulted in the isolation of one new in addition to five known compounds. This is the first report of the isolation of these six constituents from the genus *Faucaria*. All compounds, except for  $\beta$ -sitosterol, displayed a remarkable antioxidant activity, as observed using ABTS and FRAP assay methods. Isorhamnetin 3-O-rutinoside and phlorin were highlighted for their potent inhibitory activity against both tyrosinase and hyaluronidase enzymes using both in vitro and in silico testing. Overall, the obtained results support the applicability of these compounds as pigmentation modulators and means of skin remodelling in the pharmaceutical industry.

**Supplementary Materials:** The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/molecules28196895/s1>, Figure S1:  $^1\text{H}$  NMR spectrum of compound 1 (400 MHz,  $\text{CD}_3\text{OD}$ ); Figure S2: DEPT-Q spectrum of compound 1 (100 MHz,  $\text{CD}_3\text{OD}$ ); Figure S3:  $^1\text{H}$  NMR spectrum of compound 2 (400 MHz,  $\text{CD}_3\text{OD}$ ); Figure S4: DEPT-Q spectrum of compound 2 (100 MHz,  $\text{CD}_3\text{OD}$ ); Figure S5: HMBC spectrum of compound 2; Figure S6:  $^1\text{H}$  NMR spectrum of compound 3 (400 MHz,  $\text{CD}_3\text{OD}$ ); Figure S7: Negative-mode HR-ESI-MS spectrum of compound 4;



Figure S8:  $^1\text{H}$  NMR spectrum of compound 4 (400 MHz,  $\text{CD}_3\text{OD}$ ); Figure S9: DEPT-Q spectrum of compound 4 (100 MHz,  $\text{CD}_3\text{OD}$ ); Figure S10: HSQC spectrum of compound 4; Figure S11: HMBC spectrum of compound 4; Figure S12: NOESY spectrum of compound 4; Figure S13: Expanded NOESY spectrum of compound 4; Figure S14:  $^1\text{H}$  NMR spectrum of compound 5 (400 MHz,  $\text{CD}_3\text{OD}$ ); Figure S15: DEPT-Q spectrum of compound 5 (100 MHz,  $\text{CD}_3\text{OD}$ ).

**Author Contributions:** Conceptualization: H.S.A., H.A., M.A.M., A.I.O. and N.A., Formal analysis: N.A., A.I.O. and H.S.A., investigation H.S.A., M.A.M., H.A. and N.A., resources: E.A., H.W.D., A.S.A. and I.A.N. writing original data: H.S.A., I.A.N., M.A.M., H.W.D., A.S.A. and N.A., writing—review and editing: E.A., H.S.A., M.A.M. and N.A. All authors have read and agreed to the published version of the manuscript.

**Funding:** This current work was funded by the Researchers Supporting Project number (RSPD2023R812), King Saud University, Riyadh, Saudi Arabia, and Researchers Supporting Project number (PNURSP2023R342), Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** All data generated or analyzed during this study are available in this published article and the provided supplementary materials.

**Acknowledgments:** The authors extend their appreciation to the Researchers Supporting Project number (RSPD2023R812), King Saud University, Riyadh, Saudi Arabia, for funding this work. The authors extend their appreciation to Princess Nourah bint Abdulrahman University Researchers Supporting Project number (PNURSP2023R342), Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia, for supporting this work.

**Conflicts of Interest:** The authors declare that they have no conflict of interest.

**Sample Availability:** Not available.

## References

1. Abd El-Raouf, H.S. Taxonomic significance of leaves in family Aizoaceae. *Saudi J. Biol. Sci.* **2021**, *28*, 512–522. [[CrossRef](#)] [[PubMed](#)]
2. Bakr, R.O. A Comprehensive Review of the Aizoaceae Family: Phytochemical and Biological Studies. *Nat. Prod. J.* **2021**, *11*, 288–304. [[CrossRef](#)]
3. Glavich, T. Beginner's Guide to *Faucaria*. *Cactus Succul. J.* **2016**, *88*, 290–292. [[CrossRef](#)]
4. Schwantes, G.; Higgins, V. *Flowering Stones and Mid-Day Flowers: A Book for Plant and Nature Lovers on the Mesembryanthemaceae*; E. Benn: London, UK, 1957.
5. Graf, A.B. *Pictorial Cyclopedia of Exotic Plants from Tropical and Near-Tropic Regions: Guide to Care of Plants Indoors, Horticultural Color Guide, Plant Geography*; Roehr: Cincinnati, OH, USA, 1976.
6. Zhu, Y.; Yu, X.; Ge, Q.; Li, J.; Wang, D.; Wei, Y.; Ouyang, Z. Antioxidant and anti-aging activities of polysaccharides from *Cordyceps cicadae*. *Int. J. Biol. Macromol.* **2020**, *157*, 394–400. [[CrossRef](#)] [[PubMed](#)]
7. Widowati, W.; Fauziah, N.; Herdiman, H.; Afni, M.; Afifah, E.; Kusuma, H.S.W.; Nufus, H.; Arumwardana, S.; Rihibiha, D.D. Antioxidant and anti aging assays of *Oryza sativa* extracts, vanillin and coumaric acid. *J. Nat. Remedies* **2016**, *16*, 88–99. [[CrossRef](#)]
8. Younis, M.M.; Ayoub, I.M.; Mostafa, N.M.; El Hassab, M.A.; Eldehna, W.M.; Al-Rashood, S.T.; Eldahshan, O.A. GC/MS profiling, anti-collagenase, anti-elastase, anti-tyrosinase and anti-hyaluronidase activities of a *Stenocarpus sinuatus* leaves extract. *Plants* **2022**, *11*, 918. [[CrossRef](#)]
9. Masaki, H. Role of antioxidants in the skin: Anti-aging effects. *J. Dermatol. Sci.* **2010**, *58*, 85–90. [[CrossRef](#)]
10. Mukherjee, P.K.; Biswas, R.; Sharma, A.; Banerjee, S.; Biswas, S.; Katiyar, C. Validation of medicinal herbs for anti-tyrosinase potential. *J. Herb. Med.* **2018**, *14*, 1–16. [[CrossRef](#)]
11. Fayad, S.; Morin, P.; Nehmé, R. Use of chromatographic and electrophoretic tools for assaying elastase, collagenase, hyaluronidase, and tyrosinase activity. *J. Chromatogr. A* **2017**, *1529*, 1–28. [[CrossRef](#)]
12. Youssif, K.; Elshamy, A.; Rabeh, M.; Gabr, N.; Haggag, E. A Phytochemical and Biological Review on Plants of The family Aizoaceae. *J. Adv. Pharm. Res.* **2019**, *3*, 158–181. [[CrossRef](#)]
13. Bazzicalupo, M.; Cornara, L.; Burlando, B.; Cascini, A.; Denaro, M.; Smeriglio, A.; Trombetta, D. *Carpobrotus edulis* (L.) NE Br. extract as a skin preserving agent: From traditional medicine to scientific validation. *J. Integr. Med.* **2021**, *19*, 526–536. [[CrossRef](#)] [[PubMed](#)]
14. Kalicharan, B.; Naidoo, Y.; van Staden, J. Ethnopharmacology and biological activities of the Aizoaceae. *J. Ethnopharmacol.* **2022**, *303*, 115988. [[CrossRef](#)] [[PubMed](#)]

15. Åyräs, P.; Widén, C.J. NMR spectroscopy of naturally occurring phloroglucinol derivatives. *Planta Medica* **1978**, *34*, 144–152. [[CrossRef](#)]
16. Foo, L.Y.; Karchesy, J.J. Polyphenolic glycosides from Douglas fir inner bark. *Phytochemistry* **1989**, *28*, 1237–1240.
17. ERSÖZ, T.; HARPUT, Ü.Ş.; SARACOĞLU, İ.; ÇALIŞ, İ.; OGIHARA, Y. Phenolic compounds from *Scutellaria pontica*. *Turk. J. Chem.* **2002**, *26*, 581–588.
18. Andersen, O.M.; Markham, K.R. *Flavonoids: Chemistry, Biochemistry and Applications*; CRC press: Boca Raton, FL, USA, 2005.
19. Beck, M.-A.; Häberlein, H. Flavonol glycosides from *Eschscholtzia californica*. *Phytochemistry* **1999**, *50*, 329–332. [[CrossRef](#)] [[PubMed](#)]
20. Afifi, N.I.; Moawad, A.S.; Hetta, M.H.; Mohammed, R.M. Phytochemical composition and antioxidant activity of two species related to family Arecaceae. *Pharm. Sci. Asia* **2022**, *49*, 43–50. [[CrossRef](#)]
21. Lou, H.; Yamazaki, Y.; Sasaki, T.; Uchida, M.; Tanaka, H.; Oka, S. A-type proanthocyanidins from peanut skins. *Phytochemistry* **1999**, *51*, 297–308. [[CrossRef](#)]
22. Alejo-Armijo, A.; Salido, S.a.; Altarejos, J.n. Synthesis of A-type proanthocyanidins and their analogues: A comprehensive review. *J. Agric. Food Chem.* **2020**, *68*, 8104–8118. [[CrossRef](#)]
23. de Moura Martins, C.; de Moraes, S.A.; Martins, M.M.; Cunha, L.C.; da Silva, C.V.; Teixeira, T.L.; Santiago, M.B.; de Aquino, F.J.; Nascimento, E.A.; Chang, R. Antifungal and cytotoxicity activities and new proanthocyanidins isolated from the barks of *Inga laurina* (Sw.) Willd. *Phytochem. Lett.* **2020**, *40*, 109–120. [[CrossRef](#)]
24. Afifi, N.I.; Moawad, A.S.; Zaki, M.A.; Rateb, M.E.; Rashed, M.H.; Saleh, I.G.; Hetta, M.H.; Mohammed, R.M. Four new phenolics and antiparasitic secondary metabolites from *Flacourtia rukam* Zoll. & Mortizi. *Nat. Prod. Res.* **2022**, *36*, 3626–3637. [[PubMed](#)]
25. Cronjé, A.; Burger, J.F.; Brandt, E.V.; Kolodziej, H.; Ferreira, D. Assessment of 3, 4trans and 3, 4-cis relative configurations in the a-series of (4, 8)-linked proanthocyanidins. *Tetrahedron Lett.* **1990**, *31*, 3789–3792. [[CrossRef](#)]
26. Liochev, S.I. Reactive oxygen species and the free radical theory of aging. *Free. Radic. Biol. Med.* **2013**, *60*, 1–4. [[CrossRef](#)] [[PubMed](#)]
27. Hussain, F.; Kayani, H.U.R. Aging-Oxidative stress, antioxidants and computational modeling. *Heliyon* **2020**, *6*, e04107.
28. Hajam, Y.A.; Rani, R.; Ganie, S.Y.; Sheikh, T.A.; Javaid, D.; Qadri, S.S.; Pramodh, S.; Alsulimani, A.; Alkhanani, M.F.; Harakeh, S. Oxidative stress in human pathology and aging: Molecular mechanisms and perspectives. *Cells* **2022**, *11*, 552. [[CrossRef](#)] [[PubMed](#)]
29. Rice-Evans, C.A.; Miller, N.J.; Paganga, G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. *Free. Radic. Biol. Med.* **1996**, *20*, 933–956. [[CrossRef](#)]
30. Zhou, H.-C.; Lin, Y.-M.; Li, Y.-Y.; Li, M.; Wei, S.-D.; Chai, W.-M.; Tam, N.F.-y. Antioxidant properties of polymeric proanthocyanidins from fruit stones and pericarps of *Litchi chinensis* Sonn. *Food Res. Int.* **2011**, *44*, 613–620. [[CrossRef](#)]
31. Kim, J.S.; Lee, J.H. Antioxidant and anti-inflammatory activity of phloroglucinol from seaweeds. *FASEB J.* **2016**, *30*, 1174.12.
32. Dede, E.; Genc, N.; Elmastas, M.; Aksit, H.; Erenler, R. Chemical constituents isolated from *Rhododendron ungueri* with antioxidant profile. *Nat. Prod. J.* **2019**, *9*, 238–243. [[CrossRef](#)]
33. Xiao, Z.; He, L.; Hou, X.; Wei, J.; Ma, X.; Gao, Z.; Yuan, Y.; Xiao, J.; Li, P.; Yue, T. Relationships between structure and antioxidant capacity and activity of glycosylated flavonols. *Foods* **2021**, *10*, 849. [[CrossRef](#)]
34. Mahmoud, A.A.; Al-Shihry, S.S.; Hegazy, M.-E.F. Biological activity of a phloroglucinol glucoside derivative from *Conyza aegyptiaca*. *Z. Für Naturforschung C* **2009**, *64*, 513–517. [[CrossRef](#)] [[PubMed](#)]
35. Hou, J.-P.; Wu, H.; Wang, Y.; Weng, X.-C. Isolation of some compounds from nutmeg and their antioxidant activities. *Czech J. Food Sci.* **2012**, *30*, 164–170. [[CrossRef](#)]
36. Ghalloo, B.A.; Khan, K.-u.-R.; Ahmad, S.; Aati, H.Y.; Al-Qahtani, J.H.; Ali, B.; Mukhtar, I.; Hussain, M.; Shahzad, M.N.; Ahmed, I. Phytochemical profiling, in vitro biological activities, and in silico molecular docking studies of *Dracaena reflexa*. *Molecules* **2022**, *27*, 913. [[CrossRef](#)] [[PubMed](#)]
37. Waksmundzka-Hajnos, M.; Sherma, J.; Kowalska, T. *Thin Layer Chromatography in Phytochemistry*; CRC Press: Boca Raton, FL, USA, 2008.
38. Jimoh, M.O.; Afolayan, A.J.; Lewu, F.B. Antioxidant and phytochemical activities of *Amaranthus caudatus* L. harvested from different soils at various growth stages. *Sci. Rep.* **2019**, *9*, 12965. [[CrossRef](#)] [[PubMed](#)]
39. Bakar, M.F.A.; Mohamed, M.; Rahmat, A.; Fry, J. Phytochemicals and antioxidant activity of different parts of bambangan (*Mangifera pajang*) and tarap (*Artocarpus odoratissimus*). *Food Chem.* **2009**, *113*, 479–483. [[CrossRef](#)]
40. Liangli, L.Y. *Wheat Antioxidants*; John Wiley & Sons: Hoboken, NJ, USA, 2008.
41. Sánchez, C.S.; González, A.T.; García-Parrilla, M.; Granados, J.Q.; De La Serrana, H.L.G.; Martínez, M.L. Different radical scavenging tests in virgin olive oil and their relation to the total phenol content. *Anal. Chim. Acta* **2007**, *593*, 103–107. [[CrossRef](#)]
42. Zafar, R.; Ullah, H.; Zahoor, M.; Sadiq, A. Isolation of bioactive compounds from *Bergenia ciliata* (haw.) Sternb rhizome and their antioxidant and anticholinesterase activities. *BMC Complement. Altern. Med.* **2019**, *19*, 296. [[CrossRef](#)]
43. Ferreira, I.C.; Baptista, P.; Vilas-Boas, M.; Barros, L. Free-radical scavenging capacity and reducing power of wild edible mushrooms from northeast Portugal: Individual cap and stipe activity. *Food Chem.* **2007**, *100*, 1511–1516. [[CrossRef](#)]
44. El-Nashar, H.A.; El-Labbad, E.M.; Al-Azzawi, M.A.; Ashmawy, N.S. A new xanthone glycoside from *Mangifera indica* L.: Physicochemical properties and in vitro anti-skin aging activities. *Molecules* **2022**, *27*, 2609. [[CrossRef](#)]

45. Ibrahim, N.; Abbas, H.; El-Sayed, N.S.; Gad, H.A. Rosmarinus officinalis L. hexane extract: Phytochemical analysis, nanoencapsulation, and in silico, in vitro, and in vivo anti-photoaging potential evaluation. *Sci. Rep.* **2022**, *12*, 13102. [[CrossRef](#)]
46. Roselan, M.A.; Zakaria, N.; Faujan, N.H.; Latif, M.A.M.; Faudzi, S.M.M.; Ab Hadi, H.; Ashari, S.E. In vitro cytotoxicity assay, mushroom tyrosinase inhibitory activity and release analysis of kojic monooleate nanodelivery system and in silico molecular docking study against 2Y9X target enzyme. *J. Drug Deliv. Sci. Technol.* **2021**, *66*, 102764. [[CrossRef](#)]
47. Sepehri, N.; Iraj, A.; Yavari, A.; Asgari, M.S.; Zamani, S.; Hosseini, S.; Bahadorikhalili, S.; Pirhadi, S.; Larijani, B.; Khoshneviszadeh, M. The natural-based optimization of kojic acid conjugated to different thio-quinazolinones as potential anti-melanogenesis agents with tyrosinase inhibitory activity. *Bioorganic Med. Chem.* **2021**, *36*, 116044. [[CrossRef](#)] [[PubMed](#)]
48. Mansour, M.A.; AboulMagd, A.M.; Abdel-Rahman, H.M. Quinazoline-Schiff base conjugates: In Silico study and ADMET predictions as multi-target inhibitors of coronavirus (SARS-CoV-2) proteins. *RSC Adv.* **2020**, *10*, 34033–34045. [[CrossRef](#)] [[PubMed](#)]
49. El-Hawary, S.S.; Mohammed, R.; Taher, M.A.; AbouZid, S.F.; Mansour, M.A.; Almahmoud, S.A.; Huwaimel, B.; Amin, E. Characterization of Promising Cytotoxic Metabolites from *Tabebuia guayacan* Hemsl.: Computational Prediction and In Vitro Testing. *Plants* **2022**, *11*, 888. [[CrossRef](#)]
50. El-Hawary, S.S.; Mohammed, R.; Lithy, N.M.; AbouZid, S.F.; Mansour, M.A.; Almahmoud, S.A.; Huwaimel, B.; Amin, E. Digalloyl glycoside: A potential inhibitor of trypanosomal PFK from *Euphorbia abyssinica* JF Gmel. *Plants* **2022**, *11*, 173. [[CrossRef](#)]
51. Abdel-Azziz, I.A.; Amin, N.H.; El-Saadi, M.T.; Abdel-Rahman, H.M. Design, synthesis and mechanistic studies of benzophenones hydrazone derivatives as cathepsin inhibitors. *J. Mol. Struct.* **2023**, *1274*, 134583. [[CrossRef](#)]
52. Shaker, A.M.; Shahin, M.I.; AboulMagd, A.M.; Aleem, S.A.A.; Abdel-Rahman, H.M.; Abou El Ella, D.A. Novel 1, 3-diaryl pyrazole derivatives bearing methylsulfonyl moiety: Design, synthesis, molecular docking and dynamics, with dual activities as anti-inflammatory and anticancer agents through selectively targeting COX-2. *Bioorganic Chem.* **2022**, *129*, 106143. [[CrossRef](#)]
53. Altyar, A.E.; Ashour, M.L.; Youssef, F.S. *Premna odorata*: Seasonal metabolic variation in the essential oil composition of its leaf and verification of its anti-ageing potential via in vitro assays and molecular modelling. *Biomolecules* **2020**, *10*, 879. [[CrossRef](#)]
54. Juszcak, A.M.; Marijan, M.; Jakupović, L.; Tomczykowa, M.; Tomczyk, M.; Zovko Končić, M. Glycerol and Natural Deep Eutectic Solvents Extraction for Preparation of Luteolin-Rich *Jasione montana* Extracts with Cosmeceutical Activity. *Metabolites* **2023**, *13*, 32. [[CrossRef](#)]
55. Gębalski, J.; Graczyk, F.; Załuski, D. Paving the way towards effective plant-based inhibitors of hyaluronidase and tyrosinase: A critical review on a structure–activity relationship. *J. Enzym. Inhib. Med. Chem.* **2022**, *37*, 1120–1195. [[CrossRef](#)]
56. Meyer-Almes, F.-J. Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design. *Comput. Biol. Chem.* **2020**, *88*, 107351. [[CrossRef](#)] [[PubMed](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.